ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1608844
This article is part of the Research TopicNext-Generation Treatment for Pediatric Cancer: Advancing Immunotherapy through CombinationsView all articles
Safety and Efficacy of Sintilimab versus Pembrolizumab in the Treatment of Advanced or Recurrent Pediatric Malignancies: A Real-World Study in China
Provisionally accepted
Lei Mao
Meng Li
Linnan Wu
Juan Wang
Yi Que
Sun Feifei
Junting Huang
Suying Lu
Zijun Zhen
Jia Zhu*
Mengjia Song*
Yizhuo Zhang*- Department of Pediatric Oncology, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Programmed death receptor 1 (PD-1) inhibitors have shown durable response and mild adverse events in adult malignancies. However, study on PD-1 inhibitors in pediatric patients remains limited, and a direct comparison of distinct PD-1 inhibitors in pediatric tumors is lacking.We conducted a retrospective analysis of 75 pediatric patients with advanced or recurrent malignancies treated with either Sintilimab-based (n=53) or Pembrolizumab-based (n=22) regimens. The primary endpoints included treatment-related adverse events (TRAEs) and objective response rate (ORR), and the second endpoints included progression-free survival (PFS) and overall survival (OS).
Keywords: Pediatric malignancies, PD-1 inhibitors, Sintilimab, Pembrolizumab, Safety, efficacy
Received: 09 Apr 2025; Accepted: 20 May 2025.
Copyright: © 2025 Mao, Li, Wu, Wang, Que, Feifei, Huang, Lu, Zhen, Zhu, Song and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jia Zhu, Department of Pediatric Oncology, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, China
Mengjia Song, Department of Pediatric Oncology, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, China
Yizhuo Zhang, Department of Pediatric Oncology, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center (SYSUCC), Guanghzou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.